Table 3.
Study | N | Regimen | % platinum-resistant (<6 months) | Overall RR | Platinum-resistant RR | Median PFS | Median OS |
---|---|---|---|---|---|---|---|
ten Bokkel | 114 | Paclitaxel | 52% | 13% | 7% | 14 weeks | 43 weeks |
Huinink et al24 | 112 | Topotecan | 54% | 21% | 13% | 23 weeks | 61 weeks |
Gordon et al23 | 239 | Liposomal doxorubicin | 54% | 20% | 12% | 18 weeks | 60 weeks |
235 | Topotecan | 53% | 17% | 7% | 17 weeks | 57 weeks P = 0.038 | |
O’Byrne et al25 | 107 | Liposomal doxorubicin | 60% | 19% | 22 weeks | 46 weeks | |
107 | Paclitaxel | 63% | 23% | 22 weeks | 56 weeks | ||
Gore et al26 | 266 | Topotecan (PO) | 13% | 8% | 13 weeks | 51 weeks | |
Topotecan (IV) | 20% | 8% | 17 weeks | 58 weeks | |||
Mutch et al27 | 195 | Liposomal doxorubicin | 8.3% | 3.1 months | 13.5 months | ||
Gemcitabine | 6.1% | 3.6 months | 12.7 months |
Abbreviations: IV, intravenously; N, number; OS, overall survival; PFS, progression-free survival; PO, oral administration; RR, relative risk.